EMD Serono

234 articles about EMD Serono

• New Real-World MAVENCLAD® Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients

  10/13/2021

  New Real-World MAVENCLAD ® Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients

• EMD Serono Completes Enrollment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021

  10/4/2021

  EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced enrollment has been completed in the Phase III EVOLUTION RMS clinical trial program, which is evaluating the efficacy and safety of investigational Bruton’s tyrosine kinase inhibitor evobrutinib in patients with relapsing multiple sclerosis.

• EMD Serono to Present Latest Highlights From Oncology Portfolio at WCLC and ESMO 2021

  9/12/2021

  EMD Serono announced research from Company-sponsored, investigator-sponsored, and collaborative studies — including two oral and two mini-oral presentations — at this year’s World Conference on Lung Cancer, September 8-14, 2021, and the European Society for Medical Oncology Congress, September 16-21, 2021.

• Data from EMD Serono’s Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21

  5/19/2021

  New analyses from pivotal BAVENCIO® study reinforce unique clinical benefits across different subgroups in the treatment of advanced urothelial carcinoma

• EMD Serono Announces New Data Strengthening Evidence for Use of MAVENCLAD During the COVID-19 Pandemic

  4/28/2021

  EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis (RMS) treated with MAVENCLAD® (cladribine) tablets,

• EMD Serono Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic

  4/23/2021

  EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis (RMS) treated with MAVENCLAD® (cladribine) tablets, which may contribute to their ability to fight infections and develop protective antibodies from vaccines.

• Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS

  4/16/2021

  EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology Annual Meeting showing that the investigational Bruton’s tyrosine kinase inhibitor evobrutinib significantly reduced blood neurofilament light chain levels, a key biomarker of neuronal damage and inflammation, in patients with multiple sclerosis.

• EMD Serono Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent

  4/12/2021

  US National Cancer Institute led Phase II clinical study met its primary objective with 36% confirmed ORR, and showed durable responses 1 A new company-sponsored, global clinical trial will further assess berzosertib in small cell lung cancer

• New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines

  2/25/2021

   EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of a new analysis from the MAGNIFY-MS study on MAVENCLAD® (cladribine) tablets in patients with relapsing multiple sclerosis (RMS) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021

• Real-World Evidence Study at Miami CFAR Suggests HIV-Associated Wasting Remains an Underappreciated Comorbidity

  2/9/2021

  EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, presented retrospective HIV-associated wasting (HIVAW) prevalence and comorbidity data today from a claims database analysis at the Miami Center for AIDS Research (CFAR) Conference on HIV and Aging in the Era of ART and COVID-19

• FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations

  2/3/2021

  - TEPMETKO is approved for both treatment naïve and previously treated METex14 positive NSCLC patients - TEPMETKO demonstrated consistent and durable responses in both treatment naïve and previously treated METex14 patients in the VISION study - VISION is the largest clinical study to date of patients with metastatic NSCLC with MET exon 14 skipping alterations

• European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

  1/25/2021

  BAVENCIO maintenance treatment significantly extended median overall survival versus standard of care in the Phase III JAVELIN Bladder 100 study

• EMD Serono Appoints Manuel Zafra as New Managing Director for Canada

  1/6/2021

  EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, is pleased to announce the appointment of Manuel Zafra as the new Managing Director for Canada.

• EMD Serono's Embracing Carers™ Announces Study Results on COVID-19 and Caregivers

  11/18/2020

  Embracing Carers™, a global initiative led by EMD Serono, raises awareness about the often-overlooked needs of unpaid caregivers and develops solutions collaboratively with global caregiving organizations.

• Merck KGaA, Darmstadt, Germany, Recognized for Collaborative Cancer Research by CEO Roundtable on Cancer

  11/10/2020

  The CEO Roundtable on Cancer has recognized the healthcare business of Merck KGaA, Darmstadt, Germany, operating as EMD Serono in the US and Canada, with the 2020 Dr. Charles A. Sanders Award for collaborative scientific research in cancer.

• BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine

  9/18/2020

  EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print in The New England Journal of Medicine.

• EMD Serono to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis

  9/3/2020

  - Company to present 54 abstracts across its MS portfolio - MAVENCLAD® (cladribine) tablets, Rebif® (interferon beta-1a) and investigational evobrutinib - New data and real-world evidence further characterize the efficacy and safety profiles of MAVENCLAD® - New MAVENCLAD® and Rebif® safety data to be shared regarding risk of respiratory viral infections

• FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

  6/30/2020

  EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO®

• 

  Biopharma Update on the Novel Coronavirus: June 26

  6/26/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.

• EMD Serono Initiates First Clinical Trial of TLR7 and 8 Inhibitor as a Potential Treatment for Severe Symptoms of Covid-19 Infection

  6/25/2020

  - Novel mechanism will be studied for the first time to potentially show a reduction in the inflammatory response that can lead to 'cytokine storm' in patients with Covid-19 pneumonia - TLR7 and TLR8 are innate immune sensors that detect single-stranded (ss) RNA from viruses such as SARS-CoV-2 - Results from the Phase II study expected by the end of 2020   [25-June-2020]